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A gluten challenge in celiac patients provides a unique
opportunity to study the immunology associated with the
transition from relative health to autoimmunity. This study
showed that a B-cell population in peripheral blood corre-
lated inversely with gluten-dependent small intestinal
lesions, implicating a protective mechanism.
BACKGROUND & AIMS: Celiac disease (CeD) provides an
opportunity to study autoimmunity and the transition in im-
mune cells as dietary gluten induces small intestinal lesions.
METHODS: Seventy-three celiac disease patients on a long-
term, gluten-free diet ingested a known amount of gluten
daily for 6 weeks. A peripheral blood sample and intestinal
biopsy specimens were taken before and 6 weeks after initi-
ating the gluten challenge. Biopsy results were reported on a
continuous numeric scale that measured the villus-
height–to–crypt-depth ratio to quantify gluten-inducedintestinal injury. Pooled B and T cells were isolated from whole
blood, and RNA was analyzed by DNA microarray looking for
changes in peripheral B- and T-cell gene expression that
correlated with changes in villus height to crypt depth, as
patients maintained a relatively healthy intestinal mucosa or
deteriorated in the face of a gluten challenge.
RESULTS: Gluten-dependent intestinal damage from baseline
to 6 weeks varied widely across all patients, ranging from no
change to extensive damage. Genes differentially expressed in B
cells correlated strongly with the extent of intestinal damage.
A relative increase in B-cell gene expression correlated with a
lack of sensitivity to gluten whereas their relative decrease
correlated with gluten-induced mucosal injury. A core B-cell
gene module, representing a subset of B-cell genes analyzed,
accounted for the correlation with intestinal injury.
CONCLUSIONS: Genes comprising the core B-cell module
showed a net increase in expression from baseline to 6 weeks
in patients with little to no intestinal damage, suggesting that
these individuals may have mounted a B-cell immune response
to maintain mucosal homeostasis and circumvent
2 Garber et al Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 1inﬂammation. DNA microarray data were deposited at the GEO
repository (accession number: GSE87629; available: https://
www.ncbi.nlm.nih.gov/geo/). (Cell Mol Gastroenterol Hepatol
2017;4:1–17; http://dx.doi.org/10.1016/j.jcmgh.2017.01.011)
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http://dx.doi.org/10.1016/j.jcmgh.2017.01.011Hin the diet that are considered foreign with respect
to the immune system. Immune cells in the small intestine
survey the contents in the intestinal environment looking
for pathogens. Oral tolerance is a mechanism that balances
the need to promote tolerance to orally administered,
foreign, yet harmless, food proteins with the need to provide
a host defense against harmful pathogens in the intestine.1
Although not well understood, oral tolerance to a food
protein is an active immune response whose function is to
suppress inﬂammatory immune responses to the same food
protein when presented to the immune system for a second
time. In celiac disease (CeD), a lack of oral tolerance
develops to a family of cereal proteins collectively referred
to as gluten,2 resulting in a pathogenic and inﬂammatory
immune response.
The small intestinal mucosa consists of an epithelium
and its underlying structures, which are immediately adja-
cent to the intestinal lumen and in contact with digested
food. To increase surface area for nutrient absorption, the
mucosa projects ﬁnger-like extensions called villi into the
lumen of the gut. At the base of the villi are proliferative
crypts. In patients with CeD, gluten ingestion results in
blunting of the villi and hypertrophy or elongation of the
crypts. The ratio of the height of the villi (Vh) to the depth of
the crypt (Cd), expressed as Vh:Cd, has been used to
quantify the extent of intestinal damage in CeD.3–8 In severe
cases, villi shrink completely with extensive crypt elonga-
tion, resulting in a ﬂat mucosa and a Vh:Cd measurement
approaching zero.
HLA-DQ is an important genetic factor that predisposes
individuals to CeD and type 1 diabetes.9,10 A total of
5%–10% of individuals with type 1 diabetes develop CeD,11
which is signiﬁcantly higher than the chance of developing
CeD in the overall Caucasian population, estimated to be
1%.12 Most CeD patients (90%) express HLA-DQ2.5,
whereas the remainder express HLA-DQ2.2 or HLA-DQ8.13
Gluten peptides that are deamidated by the self-protein
transglutaminase 2 (TG2) bind strongly to HLA-DQ and
the resulting complex is presented to HLA-DQ–restricted
CD4þ T cells,14 resulting in a T-cell response to deamidated
gluten.15 In addition to the T-cell response, gluten-
dependent, disease-speciﬁc B cells appear early during
disease pathogenesis. They precede gut damage, often are
predictive of impending disease,16–20 and produce anti-
bodies speciﬁc for deamidated gluten and TG2.21 It is un-
clear whether gluten-dependent auto-antibodies against
TG2 contribute to the disease and there is little evidence
that T cells with speciﬁcity for self-antigens drive the
disease.The B cell recognizes a speciﬁc protein antigen, such as
gluten or TG2, through direct interactions with its B-cell
receptor containing a membrane-bound immunoglobulin.22
The immunoglobulin determines antigen speciﬁcity and is
unique for each B-cell clone. B-cell receptor signaling con-
tributes strongly to B-cell proliferation and differentiation. B
cells can be antigen-presenting cells23 and have the ability
to express HLA-DQ2 or HLA-DQ8. Because gluten peptides
are excellent substrates for TG2 and the two proteins form a
transient covalent complex, the possibility exists that a
deamidated gluten- or TG2-speciﬁc B cell binds the complex
through the B-cell receptor, internalizes, and then presents
gluten on HLA-DQ2 or HLA-DQ8 at the B cell surface to a
gluten-speciﬁc HLA-DQ2– or HLA-DQ8–restricted CD4þ T
cell.15,24 In this scenario, the resulting B cell is a functional
antigen-presenting cell whose cell phenotype, as deter-
mined by B-cell–receptor signaling and direct B- and T-cell
co-stimulatory interactions, ultimately may be under the
control of gluten.
An inﬂammatory, gluten-induced immune response in
the gut may propagate systemically in peripheral blood.
The plausible trafﬁcking of B and T cells and anti-TG2 to
sites beyond the gut may help to explain several systemic
clinical manifestations of CeD,25 including dermatitis her-
petiformis, a gluten-dependent blistering skin condition.
CeD also may manifest as a bone disease,26 in the central
nervous system as ataxia and brain atrophy,27 or as an
isolated subclinical28 or severe liver disease.29 Evidence
indicates that immune cells migrate to and from the gut in
peripheral blood. For example, disease-speciﬁc T cells
expressing the gut-homing b7 integrin migrate transiently
to the periphery upon gluten challenge in CeD patients;
these T cells are inﬂammatory in nature.30,31 The periph-
eral blood therefore may be a good source to obtain bio-
markers of the disease.
It is not clear how gluten interacts with mechanisms of
peripheral immune tolerance and whether B or T cells are
responsible for disrupting the tolerogenic environment of
the small intestine. The objective of this work was to
determine if peripheral blood B and T cells modify
gene expression in response to a 6-week gluten challenge in
patients with treated CeD, and to correlate any changes in
peripheral B- or T-cell gene expression with the extent of
gluten-induced histological damage to the small intestine.Materials and Methods
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
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Intestinal biopsy specimens and whole blood samples
were collected from a single clinical site at the University of
Tampere, Tampere, Finland, with patient consent (ethics
approval ETL R09084M, ETL R10135M, and Eudra CTs
2009-012221-10 and 2010-023127-23). For each time
point, small-bowel biopsy specimens (4–7 specimens) were
sampled from the descending duodenum, sectioned, and
scored by the same evaluator using standardized morpho-
metric tools.5,32 Of the 73 patients included in this analysis,
37% were male and 63% were female. The age range was
23–74 years with a median age of 59 years. For 6 weeks,
patients ingested 6 g/day (20 patients), 3 g/day (26
patients), or 1.5 g/day (27 patients) wheat gluten with a
meal. At the baseline time point, patients (85%) were
negative for antibodies against transglutaminase 2. All
patients completed the full 6-week study.
B- and T-Cell Isolation
CD19þ B cells and CD3þ T cells were puriﬁed together
from freshly prepared, venous whole blood (14 mL) using
whole-blood CD19 and CD3 magnetic microbeads and the
whole-blood column kit as speciﬁed by the manufacturer
(Miltenyi Biotec, Bergisch Gladbach, Germany). EDTA was
used as a blood anticoagulant. The ﬁnal cell pellet contain-
ing puriﬁed B and T cells was resuspended in TRIzol (Fisher
Scientiﬁc) reagent (5 mL) to lyse the cells and protect the
RNA from degradation. The denatured B- and T-cell lysate
was stored at -70C for up to 3 months before puriﬁcation of
total RNA. For convenience, whole-blood samples may be
stored on ice for up to 1 hour before adding magnetic beads.
Preparation time from the point of adding magnetic beads to
freezing the B- and T-cell lysate was less than 2 hours.
Total RNA Preparation
Pooled B- and T-cell lysates (5 mL) denatured in TRIzol
were extracted with chloroform (0.2 vol) and the crude RNA
was precipitated from the aqueous phase with the addition
of isopropanol (0.7 vol). The RNA pellet was puriﬁed further
using the RNeasy Plus Kit (Qiagen, Hilden Germany)
according to the manufacturer’s speciﬁcations. Puriﬁed total
RNA was eluted from the spin column with the addition of
2 aliquots (35 mL) RNase-free water. An Agilent BioAnalyzer
(Santa Clara, CA) was used to determine total RNA yield
(median, 2.2 mg), purity (median A260/A280, 2.1), and size
(median RNA integrity number, 9.5) for all 146 samples.
Puriﬁed total RNA was stored at less than -60C.
Microarrays
RNA samples were converted into labeled target com-
plementary RNA (cRNA) using the Illumina TotalPrep-96
RNA Ampliﬁcation Kit (Ambion). Brieﬂy, 100 ng of total
RNA was converted to double-stranded complementary
DNA using an oligo-d(T) primer-adaptor. This complemen-
tary DNA was puriﬁed using magnetic beads and used as a
template for in vitro transcription using T7 RNA polymerase
and biotin–uridine triphosphate. The resulting biotinylated
cRNA was puriﬁed using magnetic beads and quantiﬁed byspectrophotometry. For hybridization, 750 ng of puriﬁed
biotinylated cRNA was added to Hybridization Cocktail
Buffer (Illumina), applied to arrays, and incubated at 58C
for 16 hours. After hybridization, arrays were washed and
stained using standard Illumina procedures before scanning
on an Illumina iScan instrument using the DirectHyb Tiff
setting. Scanned images were processed by the Gene
Expression module of GenomeStudio (v 1.6; Illumina) using
default parameters without normalization.
A total of 146 RNA samples were analyzed by microarray
representing 73 patients with high-quality microarray data
at baseline and 6-week time points (146 arrays). The 146
arrays included 39 from HT-12 version 3 and 107 from
HT-12 version 4 (Illumina). The version 3 arrays were dis-
continued by the manufacturer, requiring the change to
version 4. Only probes having identical sequence content
between versions were retained. Potential artifacts caused
by the 2 array versions and batch were removed by
assuming the batch medians for a given probe were equal
(covariates were not associated with batch). This was
facilitated by the fact that both baseline and 6-week time
points for 60 of 73 patients (82%) were analyzed on the
same batch. After median shifting each probe relative to
batch medians, probe quantile normalization was per-
formed across all samples. Background then was subtracted
with a monotonic transform of probe values below back-
ground to the (0,1) interval so that all normalized probes
had positive values before log transformation. After
normalization, batch adjustment, and background subtrac-
tion, the difference in expression between baseline and the
6-week time points was calculated as log2 (6-wk/baseline)
for each subject resulting in a matrix of 20,624 features and
73 samples.Gene Lists
According to Bindea et al,33 genes highly enriched in T
cells were segregated into immune subpopulations: T cell,
T CD8, T gd, T helper, T helper 1, T helper 2, T helper 17, T
central memory, T effector memory, T follicular helper, and
T regulatory. These categories were taken verbatim from
the publication as multiple lists representing T-cell sub-
populations and used separately to analyze the CeD data set.
The T-regulatory category was characterized by one gene
(FOXP3), which was not present on the Illumina array and
therefore dropped from the analysis. According to Newman
et al,34 genes highly enriched in T cells also were segregated
into immune subpopulations: CD8, CD4 naive, CD4 memory
resting, CD4 memory activated, T follicular helper, T regu-
latory, and T gd. In this case, genes representing T-cell
subpopulations were consolidated into one gene list. Genes
highly enriched in B cells were taken verbatim from the
publication as a single list (Bindea et al33) or the B-cell
subpopulations were consolidated into a single list (New-
man et al34). Bindea et al33 also provided gene lists repre-
senting a diverse set of immune cell expression phenotypes,
including mast, natural killer, neutrophils, macrophage, eo-
sinophils, dendritic, and cytotoxic cells, as well as SW480
cancer cells and normal mucosa, which were included as
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used previously as a predictor in breast cancer.35 All gene
lists used to analyze the CeD data set are shown in
Supplementary Table 1.
In whole blood, the estimate is that T cells vastly
outnumber B cells. In addition, the puriﬁed CD19þ B-cell
population used in this study should have little to no fully
differentiated CD19- plasma B cells, further reducing the
number of B cells. Given that B and T cells were puriﬁed
together, B- and T-cell genes were selected from Newman
et al34 based on the following characteristic: highly enriched
in at least one B- or T-cell subpopulation relative to other
leukocytes. In addition, for B-cell gene selection, the gene
had to show little to no expression in T cells or expression
that greatly exceeded that in T cells because the contribu-
tion of B cells to the overall pool of total RNA was relatively
small.
Genes obtained from the Affymetrix (Santa Clara, CA)
array platform (Bindea et al33 and Newman et al34
studies) that were not expressed in the CeD data set or
not present on the Illumina array platform were excluded
from analysis. There were compatibility issues with T-cell
receptor (TR) gene segments between array platforms.
The T-cell gene list obtained from Newman et al34 was
modiﬁed to retain TR transcripts by deleting Affymetrix
TR probes and substituting all TR probes on the Illumina
array if these probes were expressed in the CeD data set.
It was common for genes obtained from Bindea et al33
and Newman et al34 to correspond to multiple Illumina
DNA microarray probes. All relevant probes were
included in the analysis.
Correlation Between Gene Lists and DVh:Cd
Approximately one third of genes mapped to more than
one microarray probe. In these cases, we took two different
approaches. First, the gene was consolidated to a single
probe by taking only the probe with the greatest SD of
expression across the 73 patients. The rationale behind this
approach is that probes that perform poorly show a nearly
constant, low level of signal across the data set, and thus can
be screened out by their low variation. This approach was
referred to as genes. Second, the gene was analyzed using all
corresponding probes, as opposed to the one with highest
variation. This approach was referred to as probes. In both
cases, expression levels for all genes or probes in a given list
were averaged on log signal values, and the average
expression proﬁle across 73 patients was correlated to
DVh:Cd using Spearman rank correlation. Nearly identical
results were obtained using the median rather than the
mean expression proﬁles for both genes and probes (data
not shown) to collapse a given gene list. For determination
of the core B-cell gene module, expression levels for single
probes also were correlated to DVh:Cd using Spearman rank
correlation.
Statistical Analyses
Spearman correlations were calculated in R using the
standard cor.test routine. The signiﬁcance of the correlationwas assessed using the Student t distribution by setting
exact ¼ FALSE. The GSA module in R was used for ﬁle
parsing. The Student t test used for correlations with anti-
TG2 also was performed in R. Chi-squared analysis was
performed using Microsoft Excel (Redmond, WA).
Celiac Disease Serum Antibodies
Serum antibodies directed against TG2-IgA were
measured by enzyme-linked immunosorbent assay (Quanta
Lite h-TG-IGA; Inova Diagnostics, San Diego, CA).32 The
positive threshold was 20 intensity units.
Results
Gluten-Dependent Intestinal Damage
The data set consisted of 73 CeD patients following a
strict gluten-free diet for at least one year. Each patient
ingested 6, 3, or 1.5 g wheat gluten daily for 6 weeks. A
whole blood sample, which was used to purify B and T
cells, and intestinal biopsy specimens were taken before
(baseline) and 6 weeks after initiating the gluten challenge.
The median Vh:Cd at baseline was 2.7 (see Table 1 for
patient data). Net change in intestinal biopsy from baseline
to 6 weeks, deﬁned as DVh:Cd, showed wide variation
across all patients from no change or slight improvement to
extensive mucosal damage (Figure 1). The largest DVh:Cd
(-2.9) was observed in 3 patients who transitioned from a
relatively healthy mucosa (Vh:Cd, 3.1) to a nearly ﬂat
mucosa (Vh:Cd, 0.2) in 6 weeks. Daily gluten dose for 2 of
these patients was 6 g (roughly 2 slices of wheat bread).
Although the 6 g gluten dose in these 2 patients resulted in
extensive mucosal damage, in other patients it resulted in
no damage (Figure 1, blue bars). Similar observations were
made for the other 2 gluten doses, 3 g (yellow) and 1.5 g
(grey). As a result, gluten dose was distributed across the
full spectrum of intestinal damage. Regression analysis of
DVh:Cd vs gluten dose showed that gluten dose explained
roughly 18% of the variation in mucosal damage (adjusted
R2, 0.18; P ¼ .0001). How an individual responded to the
gluten challenge partly reﬂected the magnitude of the
gluten dose.
We were interested in wide variations in gluten-induced
DVh:Cd across the data set, which we observed. The ques-
tion we investigated in this study was whether mucosal
damage correlated with an immune response, irrespective
of the nominal amount of gluten administered daily.Genes Differentially Expressed in B and T Cells
The experimental design was to isolate only CD19þ B
cells and CD3þ T cells from whole blood, which enabled a
simpliﬁed analysis of gene expression data focusing solely
on genes highly enriched in B and T cells. With this design,
our goal was to reduce the noise associated with analyzing
global gene expression. For this purpose, we used two
published gene lists derived from DNA microarray analyses
of fractionated human leukocytes (Bindea et al33 and
Newman et al34). The overlap in the B-cell gene lists
between Bindea et al33 (23 genes) and Newman et al34
Table 1.Patient Data
Patient
ID
Vh:Cd
(time,
0 days)
Vh:Cd
(time,
42 days)
DVh:Cd
(time 0 -
time 42)
Gluten
challenge,
g/day
Age
range, y Sex
Anti–TG2-IgA
(time, 0 days)
Anti–TG2-IgA
(time, 42 days)
Anti–TG2-IgA
fold change
Anti–TG2-IgA
positivity
Z 3.1 0.2 2.9 6 41–50 F 7 216 31 Pos
X 3.1 0.2 2.9 6 51–60 F 6 8 - Neg
AV 3.1 0.2 2.9 3 61–70 F 17 183 11 Pos
O 3.5 0.7 2.8 6 51–60 F 8 146 18 Pos
P 2.7 0.2 2.5 6 41–50 F 11 227 21 Pos
AS 3.2 0.7 2.5 3 51–60 M 11 8 - Neg
M 2.9 0.5 2.4 6 61–70 M 12 19 - Neg
Y 2.8 0.4 2.4 6 51–60 F 10 10 - Neg
G 2.6 0.3 2.3 6 31–40 M 6 240 40 Pos
W 2.6 0.3 2.3 6 41–50 F 6 53 9 Pos
AF 2.7 0.4 2.3 3 41–50 M 23 40 - Baseline pos
R 3 0.8 2.2 6 61–70 F 7 10 - Neg
AW 2.8 0.6 2.2 3 41–50 F 15 85 6 Pos
K 2.4 0.3 2.1 6 41–50 F 15 282 19 Pos
CM 2.8 0.7 2.1 1.5 41–50 F 10 72 7 Pos
AQ 2.4 0.4 2 3 61–70 F 10 22 2 Pos
AY 2.6 0.6 2 3 61–70 M 12 36 3 Pos
AC 2.3 0.3 2 3 61–70 M 7 11 - Neg
V 2.6 0.7 1.9 6 61–70 F 10 133 13 Pos
CX 2.6 0.7 1.9 1.5 61–70 F 12 34 3 Pos
AP 3 1.1 1.9 3 51–60 F 8 88 11 Pos
CS 2.5 0.6 1.9 1.5 61–70 F 9 8 - Neg
AH 2.7 0.9 1.8 3 41–50 F 10 114 11 Pos
H 2 0.4 1.6 6 51–60 F 109 365 - Baseline pos
AA 2.5 0.9 1.6 3 51–60 F 25 59 - Baseline pos
AG 2.5 0.9 1.6 3 51–60 M 11 23 2 Pos
BK 2.6 1 1.6 3 41–50 M 14 24 2 Pos
S 2.8 1.2 1.6 6 61–70 F 11 14 - Neg
AN 2.9 1.3 1.6 3 41–50 F 16 5 - Neg
AU 1.7 0.2 1.5 3 61–70 M 22 21 - Baseline pos
DK 3 1.5 1.5 1.5 61–70 F 9 8 - Neg
AL 2.7 1.3 1.4 3 51–60 M 11 52 5 Pos
AI 2.5 1.2 1.3 3 51–60 F 8 95 12 Pos
AK 2.9 1.6 1.3 3 61–70 F 15 7 - Neg
AE 2.4 1.1 1.3 3 71–80 M 8 67 8 Pos
T 2.9 1.7 1.2 6 61–70 M 7 15 - Neg
AD 2.3 1.1 1.2 3 51–60 F 50 41 - Baseline pos
DF 2.6 1.5 1.1 1.5 51–60 M 6 4 - Neg
L 1.4 0.3 1.1 6 61–70 M 23 209 - Baseline pos
AM 3.3 2.2 1.1 3 51–60 F 6 6 - Neg
CE 1.3 0.4 0.9 1.5 61–70 M 10 21 2 Pos
DC 2.9 2 0.9 1.5 51–60 F 7 5 - Neg
CA 3.6 2.8 0.8 1.5 31–40 F 8 7 - Neg
DZ 3.2 2.4 0.8 1.5 61–70 F 6 5 - Neg
CG 2 1.3 0.7 1.5 61–70 F 6 8 - Neg
DQ 2.9 2.2 0.7 1.5 61–70 F 4 3 - Neg
DY 3 2.3 0.7 1.5 61–70 F 7 5 - Neg
DB 2.9 2.2 0.7 1.5 41–50 M 9 6 - Neg
C 1.1 0.5 0.6 6 21–30 F 74 239 - Baseline pos
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Table 1.Continued
Patient
ID
Vh:Cd
(time,
0 days)
Vh:Cd
(time,
42 days)
DVh:Cd
(time 0 -
time 42)
Gluten
challenge,
g/day
Age
range, y Sex
Anti–TG2-IgA
(time, 0 days)
Anti–TG2-IgA
(time, 42 days)
Anti–TG2-IgA
fold change
Anti–TG2-IgA
positivity
CN 3.1 2.5 0.6 1.5 71–80 F 14 11 - Neg
AT 2.3 1.7 0.6 3 41–50 M 25 70 - Baseline pos
DG 2.9 2.5 0.4 1.5 61–70 F 3 3 - Neg
U 2.5 2.1 0.4 6 51–60 F 15 32 2 Pos
DH 3.3 3 0.3 1.5 61–70 F 6 4 - Neg
DW 2.6 2.3 0.3 1.5 61–70 M 8 6 - Neg
A 2.9 2.6 0.3 6 41–50 F 47 43 - Baseline pos
CB 3 2.7 0.3 1.5 31–40 F 17 32 2 Pos
CJ 3 2.8 0.2 1.5 61–70 F 8 7 - Neg
DR 2.9 2.7 0.2 1.5 61–70 F 8 6 - Neg
AO 2.9 2.8 0.1 3 51–60 M 14 16 - Neg
DJ 2.7 2.6 0.1 1.5 61–70 F 16 11 - Neg
Q 2.8 2.7 0.1 6 61–70 M 13 32 2 Pos
N 2.7 2.7 0 6 51–60 M 8 10 - Neg
DN 2.3 2.3 0 1.5 61–70 M 14 12 - Neg
DP 2.8 2.8 0 1.5 51–60 M 7 6 - Neg
DM 1.3 1.4 -0.1 1.5 41–50 F 13 12 - Neg
AJ 2.5 2.6 -0.1 3 51–60 F 13 16 - Neg
DX 2.9 3.1 -0.2 1.5 61–70 F 10 6 - Neg
CT 2.8 3 -0.2 1.5 71–80 M 15 23 2 Pos
AR 2.3 2.6 -0.3 3 51–60 M 13 22 2 Pos
DA 2.4 2.8 -0.4 1.5 51–60 F 36 22 - Baseline pos
AX 2.8 3.3 -0.5 3 51–60 M 20 19 - Baseline pos
AB 2.3 3.4 -1.1 3 41–50 M 9 9 - Neg
NOTE. Parameters associated with the gluten challenge included the amount of gluten ingested daily for 42 days, the age
range (median, 59 y; range, 23–74 y), antisera directed against TG2-IgA (anti-TG2-IgA) expressed in intensity units for both
baseline and 42 days, and anti–TG2-IgA that was positive (pos) or negative (neg) above threshold (20 intensity units) at 42
days. Several patients were above threshold for anti–TG2-IgA at baseline (baseline pos). Anti–TG2-IgA fold change was
expressed in intensity units, which may or may not reﬂect linearity pending assay validation.
F, female; M, male.
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between the sum of all 11 T-cell subpopulations from
Bindea et al33 (185 genes) and the single T-cell list from
Newman et al34 (99 genes) was 33 genes. The two studies
have more agreement than one would expect by chance but
less than ideal agreement in deﬁning differential B- and T-
cell gene expression. Lymphocytes are diverse, the methods
used to purify these diverse cells vary, and differential gene
expression is a relative measure that compares expression
with other leukocytes. Given these complexities, it is bene-
ﬁcial to use both studies to deﬁne the most relevant genes.
We started with comprehensive B- and T-cell gene lists,
and ultimately set out to reﬁne these lists to obtain a gene
signature that correlated more speciﬁcally with
gluten-induced intestinal injury in CeD.
The B- and T-cell gene lists (see the Materials and
Methods section and Supplementary Table 1) obtained from
each publication were used separately to analyze the CeD
data set.DVh:Cd Correlates With B-Cell Gene Expression
By using DNA microarrays, we measured genome-wide
gene expression in a puriﬁed pool of B and T cells taken
from each patient at baseline and at the 6-week time points.
We calculated the net change (baseline to 6 weeks) in B- and
T-cell gene expression for each of the published B- and
T-cell gene lists and correlated this change with the net
change in Vh:Cd.
Results showed that the net change in expression of
B-cell genes from Bindea et al33 (corr. -0.54; P ¼ 8.7E-07)
and Newman et al34 (corr. -0.52; P ¼ 1.9E-06) correlated
(corr.) strongly with DVh:Cd (Figure 2A and B). It was a
negative correlation, which means that B-cell genes were
expressed relatively strongly in patients with little to no
DVh:Cd and relatively poorly in patients with large DVh:Cd.
Two gene lists from Bindea et al33 representing T-cell sub-
populations showed weak positive correlation to DVh:Cd,
including Th1 (corr. 0.34; P ¼ 0.2.58E-03) and Th2 (corr.
0.31; P ¼ 7.21E-03). In this case, opposite to B-cell genes,
Figure 1. Gluten-dependent intestinal mucosal injury as a clinical end point in a human clinical study. Vh:Cd, a histologic
measure of mucosal health, was determined at baseline and at the 6-week time point. DVh:Cd, deﬁned as baseline minus the
6-week Vh:Cd, represents intestinal damage (positive number) or healing (negative number) over the 6-week timeframe. The
bar graph shows the number of patients (y-axis) with a given DVh:Cd (x-axis) for a total of 73 patients. The number of patients
for a given DVh:Cd was subdivided further to indicate the amount of gluten ingested daily per patient, which was 6 (blue, 20
patients), 3 (yellow, 26 patients), and 1.5 (grey, 27 patients) grams of gluten daily for 6 weeks.
July 2017 B Cell Gene Signature in Celiac Disease 7T-cell genes were expressed relatively strongly in patients
with large DVh:Cd and relatively poorly in patients with
little to no DVh:Cd. Other T-cell gene lists deﬁned by Bindea
et al33 showed little to no correlation, including T CD8þ, T
helper, T, T central memory, T effector memory, T follicular
helper, T gd, and Th17. The T-cell gene list from Newman
et al34 also showed no correlation to DVh:Cd (corr. 0.10;
P ¼ 3.92E-01). Not surprisingly, gene lists corresponding to
other leukocytes showed little to no correlation because B
and T cells were the only cells analyzed in this study. The
University of North Carolina IgG gene signature,35 which
contains several known B-cell genes that predict favorable
outcomes in breast cancer patients, showed a moderate
negative correlation with DVh:Cd.
Nearly identical results were obtained irrespective of
whether multiple microarray probes corresponding to one
gene were reduced to a single probe (Figure 2A and B) or
whether all probes were analyzed (Figure 2C and D) (see
the Materials and Methods section).
In addition to DVh:Cd, we correlated gene expression to
baseline and end-of-study (week 6) Vh:Cd for all 73 pa-
tients. Results showed that the net change in expression of
B-cell genes from Bindea et al33 (corr. 0.49; P ¼ .1.16E-05)
and Newman et al34 (corr. 0.46; P ¼ 4.71E-05) correlated
with end-of-study Vh:Cd (Figure 2E and F) and was only
slightly weaker than that observed for DVh:Cd. The corre-
lation was positive, which suggests that a reduction in B-cell
gene expression over the 6-week gluten challenge (end-of-
study minus baseline) was associated with a smaller end-of-
study Vh:Cd. Th1 (corr. -0.31; P ¼ .0084) and Th2 (corr.
-0.30; P ¼ .011) gene expression was correlated negatively
with the end-of-study Vh:Cd, albeit modestly, which is
consistent with results obtained from the DVh:Cd analysis.
There was no correlation of gene expression with baseline
Vh:Cd (Figure 2G and H).Serum Anti-TG2 Correlates With DVh:Cd and the
Core B-Cell Gene Module
Sixty-two of 73 patients (85%) were negative at
baseline for serum antibodies directed against TG2(anti–TG2-IgA) (Table 1, threshold for positivity was 20
intensity units). For those 62 patients who were negative
at baseline, 42% seroconverted to a positive value over
the course of a 6-week gluten challenge. By using a Stu-
dent t test (unpaired, 2-sided) to compare means, and
excluding baseline-positive patients, we determined
that anti–TG2-IgA positivity correlated with DVh:Cd
(P ¼ .0029) and the core B-cell gene module (P ¼ .0022).
These results showed that anti-TG2 correlated with B-cell
gene expression as well as it did with DVh:Cd. A positive
anti-TG2 was associated with reduced B-cell gene
expression and increased intestinal damage over the
course of 6 weeks.A Subset of B-Cell Genes Drives Correlation
to DVh:Cd
In the correlation analyses, probes were averaged to
generate a mean expression proﬁle across the entire gene
list, which then was correlated to DVh:Cd; individual genes
or probes were not analyzed separately. We asked whether
all or a fraction of the genes in the two published B-cell
gene lists from Bindea et al33 and Newman et al34 corre-
lated with DVh:Cd. To deﬁne a core set of B-cell genes that
drives the correlation, all probes in the two B-cell gene
lists were consolidated into a single list and then the
probes were ranked separately based on their ability to
correlate with DVh:Cd. There were 63 unique probes be-
tween the two B-cell gene lists, representing 48 unique
genes. Of these, 28 probes representing 24 unique genes
signiﬁcantly correlated with DVh:Cd (P < .01). We deﬁned
these 28 probes as a core B-cell gene module representing
a subset of known B-cell genes (see Table 2 for genes). The
gene SPIB, present in both the Bindea et al33 and Newman
et al34 B-cell gene lists, showed the strongest correlation to
DVh:Cd (corr. -0.56; P ¼ 2.5E-07) (Supplementary
Table 2).
Expression levels for all 28 probes in the core B-cell gene
module were averaged across the data set, and the mean
expression proﬁle was correlated to DVh:Cd. The core B-cell
gene module correlated strongly with DVh:Cd (corr. -0.59;
Figure 2. Spearman rank
correlation of gene sig-
natures with the extent of
gluten-induced intestinal
injury. Gene lists obtained
from three publications
corresponded to B- and T-
cell populations, other leu-
kocytes, cancer cells, and
normal mucosa (y-axis). All
gene lists were obtained
from Bindea et al,33 except
for B- and T-cell lists from
Newman et al34 (as indi-
cated) and the University of
North Carolina (UNC) IgG
cluster from Fan et al.35 (A)
The mean expression pro-
ﬁle for a given gene list was
correlated with DVh:Cd
and the correlation was
reported on a scale of 0 to
1 (x-axis). Multiple micro-
array probes correspond-
ing to a single gene were
consolidated to a single
probe by taking only the
probe with the greatest SD
of expression across the
73 patients. (B) Signiﬁ-
cance for each correlation
in panel A was expressed
as a P value. Gene signa-
tures also were correlated
with (C) DVh:Cd, (E) end-
of-study Vh:Cd, and (G)
baseline Vh:Cd using mean
expression proﬁles and all
probes representing a
given gene. Signiﬁcance
for each correlation in
panels C, E, and G was
expressed as a P value in
panels D, F, and
H, respectively. aDC, acti-
vated dendritic cell; DC,
dendritic cell; iDC, imma-
ture dendritic cell; NK,
natural killer; Tcm, T
central memory; Tem,
T effector memory; TFH,
T follicular helper; Tgd, T
gamma delta.
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strongly with the mean expression proﬁle (Supplementary
Table 2). In contrast, for the remaining 35 B-cell probes
(24 unique genes) that correlated poorly as single probes
(P > .01), in the aggregate, the mean expression proﬁle
across all 35 probes also correlated poorly (corr. -0.24; P ¼
3.8E-02). We refer to the published B-cell genes that
correlated poorly with DVh:Cd as the non-correlating B-cellgene list (see Table 2 for genes). Correlations and P values
comparing the relative performance of relevant gene lists
are summarized in Table 3.
Point plots showed the scatter associated with the rela-
tionship between DVh:Cd and the net change in gene
expression for the single-probe SPIB (Figure 3A) and the
mean expression of all 28 probes in the core B-cell gene
module (Figure 3B). Seventy-three patients were scattered
Figure 2. (continued).
July 2017 B Cell Gene Signature in Celiac Disease 9fairly uniformly on both sides of the regression line over the
entire spectrum of intestinal damage.The Extended Core B-Cell Gene Module
Genes representing the core B-cell gene module and the
non-correlating B-cell gene list were obtained exclusivelyfrom the Bindea et al33 and Newman et al34 curated gene
lists. We asked whether the core B-cell gene module could
be used to discover additional disease-relevant genes that
were not included in the Bindea et al33 and Newman et al34
published gene lists. To this end, we took the Spearman
correlation between the mean expression proﬁle of the core
B-cell gene module and all 20,624 probes in the CeD data
Table 2.Gene Symbols and the Corresponding Illumina Microarray Probe IDs Representing the Core B-Cell Gene Module,
Non-correlating B-Cell Gene List, and the Extended Core B-Cell Gene Module
Core B-cell gene module Non-correlating B-cell gene list Extended core B-cell gene module
Gene Probe ID Gene Probe ID Gene Probe ID B-cell expression
All probes from core B-cell gene module plus the following
ADAM28 ILMN_1664631 ABCB4 ILMN_1767349 AFF3 ILMN_1775235 1
ALOX5 ILMN_1680996 BACH2 ILMN_1670695 ALS2CR13 ILMN_1739942 ND
BACH2 ILMN_2058468 BLNK ILMN_2142935 BASP1 ILMN_1651826 3
BANK1 ILMN_1661646 CCR9 ILMN_2337386 BTK ILMN_1662026 4
BCL11A ILMN_1659800 CCR9 ILMN_1664316 C22ORF13 ILMN_1764410 ND
BCL11A ILMN_1752899 CD180 ILMN_1665647 C4ORF34 ILMN_2224907 ND
BCL11A ILMN_2255133 CD1C ILMN_1654210 CD24 ILMN_2060413 4
BCL11A ILMN_2342271 CD40 ILMN_2367818 CD74 ILMN_1736567 3
BLK ILMN_1668277 CD79B ILMN_1710017 CD74 ILMN_2379644 3
BLR1 ILMN_2337928 CD79B ILMN_1785439 CD79A ILMN_1734878 4
CD19 ILMN_1782704 CD79B ILMN_2366212 CNTNAP2 ILMN_1690223 1
CD22 ILMN_1792075 COCH ILMN_1711514 CXXC5 ILMN_1745256 ND
CD37 ILMN_1786176 CR2 ILMN_1684724 CYBASC3 ILMN_2129505 ND
CD37 ILMN_2375825 CR2 ILMN_2369666 FAIM3 ILMN_1775542 2
CD40 ILMN_1779257 EAF2 ILMN_1708798 FCRLA ILMN_1691071 ND
CD72 ILMN_1723004 FCGR2B ILMN_1804174 GGA2 ILMN_1686152 3
CD79A ILMN_1659227 FCGR2B ILMN_2382403 HLA-DQB1 ILMN_1661266 2
FCER2 ILMN_1662451 FCGR2B ILMN_1660027 HLA-DRB4 ILMN_1752592 5
GNG7 ILMN_1728107 FCRL2 ILMN_1665152 KIAA0746 ILMN_1797822 3
HHEX ILMN_1762712 FCRL2 ILMN_1791329 LYN ILMN_1781155 3
HLA-DOB ILMN_1700428 KIAA0125 ILMN_1707491 MARCKS ILMN_1807042 2
HLA-DQA1 ILMN_1808405 LOC653980 ILMN_1659943 MDS028 ILMN_1701244 2
OSBPL10 ILMN_1669497 LOC91353 ILMN_2083066 NAPSB ILMN_2109416 ND
PNOC ILMN_1676003 MEF2C ILMN_1742544 PLCG2 ILMN_1815719 3
RASGRP3 ILMN_1727045 MS4A1 ILMN_2401714 PTPN6 ILMN_1738675 3
SPIB ILMN_2143314 MS4A1 ILMN_1776939 SEMA4B ILMN_1672589 ND
TCL1A ILMN_1788841 P2RX5 ILMN_1677793 SIDT2 ILMN_1791912 2
VPREB3 ILMN_1700147 P2RY14 ILMN_2258409 SNX2 ILMN_1691575 3
P2RY14 ILMN_2342835 SWAP70 ILMN_1785175 4
RALGPS2 ILMN_1654692 SYK ILMN_2059549 4
RALGPS2 ILMN_2276290 TLR10 ILMN_2414762 ND
RALGPS2 ILMN_1813703
RNASE6 ILMN_1780533
SCN3A ILMN_2387395
TNFRSF17 ILMN_1768016
NOTE. Immgen data browser (available: http://www.immgen.org/databrowser/index.html, datagroup; human immune cells,
Garvan) was used to quantify the relative amounts of B- and T-cell gene expression for 30 genes in the extended core B-cell
gene module (as indicated) using an arbitrary scale from 1 to 5: 5, expressed in B cells 10-fold more than other leukocytes; 4,
expressed in B cells 10-fold more than T cells; 3, expressed in B cells between 3- and 10-fold more than T cells; 2, expressed
in B and T cells with less than 3-fold differential; 1, poorly measured.
ND, no data.
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Bonferroni correction. Forty-three unique genes (48 probes)
(Supplementary Table 2) showed strong correlation to the
mean expression proﬁle (r > 0.7; corrected P < 8.3E-8).
Twenty-nine unique genes (31 probes) identiﬁed in this
analysis were not found in the core B-cell gene module.
The combination of the core B-cell gene module (24 genes,28 probes) with genes that shared a similar expression
proﬁle to the core module (29 genes, 31 probes) resulted in
a list of 53 genes (59 probes) referred to as the extended
core B-cell gene module (see Table 2 for genes).
The 29 genes that were added to the core B-cell gene
module in the extended list were not obtained from the
Bindea et al33 or Newman et al34 curated gene lists. To
Table 3.Spearman Correlation of B- and T-Cell Gene Lists
With DVh:Cd
Gene list Correlation P value
All B-cell genes Bindea et al33 -0.54 8.74E-07
All B-cell genes Newman et al34 -0.52 1.90E-06
Core B-cell gene module -0.59 3.30E-08
Non-correlating B-cell gene list -0.24 3.80E-02
Single-gene SPIB -0.56 2.50E-07
Extended core B-cell gene module -0.60 2.65E-08
Th1 genes Bindea et al33 0.34 2.58E-03
Th2 genes Bindea et al33 0.31 7.21E-03
All T-cell genes Newman et al34 0.10 3.92E-01
NOTE. Bindea et al33 and Newman et al34 refer to the authors
of the published B- and T-cell gene lists. Correlation was
negative or positive, as indicated. The core B-cell gene
module and non-correlating B-cell gene list were analyzed by
taking all probes for a given gene (probes). The other gene
lists used only the probe with the highest SD across the data
set (genes) (see the Materials and Methods section for more
detail). Th1 and Th2 refer to T-cell subpopulations as deﬁned
by Bindea et al.33
July 2017 B Cell Gene Signature in Celiac Disease 11determine if these 29 genes were expressed differentially in
human B cells, we used the Immunological Genome Project
(Immgen) data browser, which is based on gene expression
studies of fractionated human leukocytes (Garvan data set,
GEO GSE3982). The Garvan data set also was used in the
Bindea et al33 publication. Half of the 29 genes were
expressed differentially in B cells at levels that were at least
3–10 times higher than in T cells (Table 2). None of the 29
genes were known to be expressed differentially in T cells.
Hierarchical clustering showed that genes contained
within the extended core B-cell gene module were
expressed similarly across the 73 patients (Figure 4),
consistent with the possibility that they are expressedA B
Figure 3. Point plots comparing the net change in B-cell ge
gene SPIB or (B) the mean expression across all 28 probes in
change in B-cell gene expression (end-of-study minus baselinecoordinately in B cells. The extended module contained
notable genes, including, among others, HLA-DQA1 and
HLA-DQB1, the two subunits of HLA-DQ2 that bind gluten.
Notable genes that were absent included, among others,
MS4A1 (CD20), CD79B, CR2, and FCRL2, despite the obser-
vation that all four genes were represented by multiple
probes on the microarray. The extended core B-cell gene
module is therefore a portrait of B-cell gene expression that
correlated strongly (corr. -0.60; P ¼ 2.65E-08) with auto-
immune clinical outcomes in CeD.
Immune Response in Patients With Little to No
Gluten-Induced Intestinal Injury
Two plausible hypotheses may explain how a change in
B-cell gene expression correlates with gluten-induced
intestinal injury (DVh:Cd) over the 6-week study period.
First, patients with little to no DVh:Cd could maintain a
constant level of B-cell gene expression from their baseline
start to study conclusion, whereas those with a larger
DVh:Cd may reduce expression of B-cell genes. Alternatively,
patients with little to no DVh:Cd actually could increase B-
cell gene expression above their baseline starting levels,
whereas those with a larger DVh:Cd simply maintain or
decrease expression. In either scenario, the conclusion is the
same. A relative increase in expression of B-cell genes
correlated with tolerance to gluten (little to no DVh:Cd),
whereas their relative decrease correlated with gluten-
induced intestinal injury (larger DVh:Cd). To distinguish
between these two possibilities, we compared uncentered
microarray data from both baseline and 6-week time points.
To illustrate this point, we compared the expression of SPIB
with the mean expression of all 28 probes in the core B-cell
gene module. By 6 weeks, we found that the single-probe
SPIB (Figure 5A, top panel) and the aggregate mean
(Figure 5A, lower panel) increased expression above base-
line for most patients who showed little to no intestinal
injury (DVh:Cd  1.1; 36 patients). Conversely, in mostne expression with DVh:Cd for 73 patients. (A) The single-
the core B-cell gene module was used to analyze the net
). The regression line is shown in red.
Figure 4. Clustergram of extended core B-cell gene module using Java Treeview. Gene symbols and Illumina microarray
IDs are shown for each probe. Centered data were used to show a relative increase (red), decrease (green), or median level of
expression (black) for each gene across the 73 patient data set. Dendograms on both axes represent similarity in expression
for 59 probes (horizontal) and 73 patients (vertical). The preclustering data ﬁle is provided in Supplementary Table 3.
12 Garber et al Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 1patients with larger intestinal injury (DVh:Cd  1.2; 37
patients), both the single-probe SPIB and the aggregate
mean decreased expression relative to their baseline levels
(Figure 5A). The number of patients that increased or
decreased expression was statistically signiﬁcant
(Figure 5B). These results were used qualitatively to suggest
that patients who presented clinically with little to no
change in the intestinal biopsy after a 6-week gluten chal-
lenge actually mounted an immune response by increasing
expression of genes within the core B-cell gene module.Discussion
In CeD, the immune system mounts a response to dietary
gluten, resulting in destruction of small intestinal epithelial
cells and tissue remodeling of the gut mucosa. To date, no
immune cell in peripheral blood has been shown to corre-
late with gluten-induced intestinal mucosal damage. Our
objective was to identify such an immune cell in peripheral
blood with emphasis on B and T lymphocytes. The experi-
mental design included a gluten challenge in patients withCeD who had been following a gluten-free diet for at least a
year. We deﬁned oral tolerance from a clinical perspective
as the ability to ingest gluten in treated patients diagnosed
with CeD without showing a characteristic crypt hyper-
plastic lesion in the small intestine. In our study, the length
of time associated with the gluten challenge (6 weeks) was
otherwise sufﬁcient to cause damage in most patients. This
experimental design provided a rare and important look
into a relatively healthy immune system before and imme-
diately after a possible break in oral tolerance as study
participants relapsed to varying degrees in the context of a
well-controlled clinical study. Over the 6-week study period,
peripheral B, but not T, cells showed a relative increase in
gene expression in those individuals with an increasingly
healthy or undamaged gut mucosa. Conversely, in those
individuals with decreasing mucosal health, peripheral B
cells showed a relative decrease in gene expression. The
peripheral B cell therefore tracked with oral tolerance
across the full spectrum of intestinal damage, from no
change to a nearly ﬂat mucosa. This observation can be
interpreted in several ways. First, the peripheral B cell may
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Figure 5. Fold change in B-cell gene expression from baseline to 6 weeks. (A) Log2 transformed data were obtained from
Supplementary Table 4. To calculate the expression fold change from baseline (y-axis), the 6-week time point (visit 6 or V6) was
subtracted from baseline start (visit 2 or V2) for each of 73 patients. There was more (increase from zero), unchanged (zero), or
less (decrease from zero) RNA after the 6-week gluten challenge. For convenience, numbers on the y-axis were changed to
remove log2 transformation (fold changes of 0, 0.5, 1, and 1.5 in log2 space became fold changes of 0, 1.4, 2, and 2.8 without
log2 transformation) to reﬂect the actual magnitude of the change. Seventy-three patients (x-axis) were ordered by decreasing
gluten-induced intestinal damage (DVh:Cd) with actual DVh:Cd values of -1, 0, 1, 2, and 3 for reference. B-cell gene expression
was represented by SPIB (top panel) or the aggregate average expression of all 28 probes in the core B-cell gene module (all
probes average, lower panel). (B) Quantiﬁcation of the number of patients who increased or decreased expression of SPIB (top
panel) and core B-cell gene module (bottom panel) at the 6-week time point relative to baseline. Seventy-three patients were
segregated equally into 2 groups based on DVh:Cd  1.1 (36 patients) and  1.2 (37 patients). The chi-square test was used to
determine whether the number of patients who segregated above and below baseline for the 2 groups differed from expected
values distributed randomly.
July 2017 B Cell Gene Signature in Celiac Disease 13be a biomarker that indicates oral tolerance to gluten but
plays no functional role in dampening the inﬂammatory
process. Alternatively, peripheral B cells may function to
promote local and peripheral immune tolerance, the hall-
mark of a regulatory B cell36 whose compromised function
has been implicated in both human37 and mouse models38
of autoimmunity.
The peripheral B cells identiﬁed in this study satisfy one
requirement of a regulatory B cell in that its presence
correlates with tolerance. Unfortunately, there are no bio-
markers that are speciﬁc to regulatory B cells. These cells
are not considered a distinct developmental lineage of B
cells but rather to have acquired a tolerogenic phenotype in
response to environmental cues or speciﬁc antigen binding
to their B-cell receptor. In addition, regulatory B-cell subsets
may be distinct from one another with unique tolerogenic
phenotypes. Given these complexities, the peripheral B cellidentiﬁed in this study may fall within the functional deﬁ-
nition of regulatory B39 and T40 cells to dampen intestinal
inﬂammation.
The identiﬁcation of a functional human regulatory B cell
would have potential therapeutic implications for inﬂam-
matory and autoimmune diseases, including CeD. The
therapeutic objective would be to restore this peripheral
B-cell phenotype that, in the absence of intervention, sub-
sides along with immune tolerance. Depending on tissue
speciﬁcity and diversity of regulatory B-cell subsets,
knowledge obtained using CeD as a model for discovery also
may extend to cancer immunotherapy. B cells that migrate
into the tumor may acquire a regulatory phenotype that
overrides a local antitumor immune response. A therapeutic
objective would be to inhibit the tolerogenic phenotype of
the regulatory B cell and thus promote the immune
response to hematopoietic and solid cancers.
14 Garber et al Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 1Several patients on the high-gluten dose surprisingly
showed weak mucosal damage after the gluten challenge,
which contrasts with others in the same cohort and suggests
that a subset of CeD patients can maintain oral tolerance to
gluten, at least for 6 weeks. Gluten challenges using small
and moderate amounts of gluten (1.5–6 g/day) for short
times (6–12 wk) in well-treated adult patients with CeD
rarely have shown clinically signiﬁcant mucosal deteriora-
tion in all patients. Approximately 30% of subjects did not
respond to the short-term gluten challenge.6,32,41 To address
the issue of oral tolerance longer term, it was observed that
the prevalence of CeD in Finland is increasing from child-
hood (1.5%),42 through adults (2.0%),43 to the elderly
(2.7%).44 Although these data can be interpreted several
ways, one interpretation is that oral tolerance to gluten is
established early and that a break to oral tolerance is more
probable later in life after decades of gluten consump-
tion.44,45 Similarly, when volunteers previously diagnosed
with CeD reverted from a gluten-free to a gluten-containing
diet many years after their initial diagnosis and with the
disease currently in remission, there were subjects who did
not break oral tolerance to gluten for more than 2 years.46
One patient relapsed after 7 years and another went 19
years on an unrestricted, gluten-containing diet before the
disease relapsed as dermatitis herpetiformis, a gluten-
dependent clinical manifestation of CeD.47 These clinical
examples suggest that there are mechanisms in at least
some CeD patients that promote oral tolerance to gluten.
The B-cell gene signature provides biomarkers that may
track this tolerogenic, protective mechanism.
The classic deﬁnition of oral tolerance is the ability to
suppress immune responses to dietary food proteins, such
as gluten. We deﬁned oral tolerance to gluten from a clinical
perspective, regardless of an immunologic mechanism.
From a mechanistic perspective, the regulatory T cell is one
possible tolerogenic, protective, cellular mechanism that is
known to play a role in suppressing immune responses to
dietary food proteins. Most peripheral regulatory T cells in
the murine small intestine are induced by dietary proteins
from solid foods.48 The dietary proteins from wheat gluten
are apparently no exception. Type 1 regulatory T cells
conferred oral tolerance to wheat gluten in a murine model
of gluten tolerance.49 Macrophages degraded the gluten
proteins that in turn stimulated type 1 regulatory T-cell
differentiation.50 Oral tolerance is a poorly understood
process that involves multiple immune cell populations. We
provide correlative evidence in the context of relevant hu-
man studies that a regulatory B cell is a strong candidate to
promote oral tolerance to gluten.
How a patient responds to a gluten challenge may
depend on several variables, including but not limited to the
amount of gluten administered, the length of time associated
with the challenge, the length of time and stringency of the
gluten-free diet, the immune responses that control oral
tolerance to gluten, and baseline level of gluten-dependent
mucosal injury. Two of these variables deserve further
comment. First, it was required that each patient remain on
a gluten-free diet for at least one year before enrolling in the
study, providing the best possible opportunity to respond toa gluten challenge. In practice, it is nearly impossible to
assess the stringency of their gluten-free diet to determine if
the patient intentionally but only occasionally consumes
gluten, if they risk eating out where they have less control,
or if their food source inadvertently is contaminated with
gluten. These are limitations associated with human studies
that are nearly impossible to quantify. Second, on the last
point regarding baseline injury, we observed heterogeneity
in baseline Vh:Cd measurements (range, 1.1–3.5), which is a
limitation of the study that likely reﬂects a variability in the
CeD population on a gluten-free diet.51 Patients with the
highest mucosal injury (Vh:Cd of 1.1, 1.3, and 1.4) still
showed further mucosal damage following the 6-week
gluten challenge. Ongoing mucosal injury did not preclude
a gluten response. It is not known whether patients with
ongoing gluten-dependent mucosal injury (smaller Vh:Cd)
respond differently to a gluten challenge than patients with
less injury (larger Vh:Cd). It is true that patients who start
with a Vh:Cd of 1.1 cannot decrease as far as those who start
with a Vh:Cd of 3. This may reduce the dynamic range of our
analysis, however, it may be less of a concern if a relatively
small DVh:Cd associated with more baseline injury also
reﬂects a relatively small change in B-cell gene expression.
Despite any limitations, we showed strong and important
correlations between B-cell gene expression and gluten-
dependent gut mucosal injury, which implicates a cellular
mechanism of gut inﬂammation for future study.
A deliberate gluten challenge sometimes is needed to
diagnose CeD. A suspected CeD patient may initiate and
maintain a gluten-free diet without obtaining a deﬁnitive
diagnosis. In such instances, to subsequently diagnose the
disease, the patient faces the difﬁcult decision to maintain
a prolonged gluten challenge followed by serologic tests
and potentially undergoing repeated upper gastrointes-
tinal endoscopies with small intestinal biopsies, as the
patient waits for the break in oral tolerance to gluten. The
strong correlation we observed between B-cell gene
expression and DVh:Cd suggests that the B-cell signature
may be a useful diagnostic tool in this context. Develop-
ment of such a predictive model will require an accurate
determination of the cumulative error associated with
measuring DVh:Cd. Errors include sampling (number and
location), sectioning, and scoring5 intestinal biopsy spec-
imens. Ultimately, biomarkers developed from a periph-
eral B-cell signature may be used to monitor changes in
local gut inﬂammation from one time point to another.
Validation studies should conﬁrm our observation that
individuals with CeD vary in their sensitivity or degree of
tolerance to gluten, at least by 6 weeks, and that all in-
dividuals in this study may have relapsed given more than
6 weeks on a gluten challenge. We hypothesize that the B-
cell signature will correlate with relapse when the break
to immune tolerance ultimately is observed. It also is
noteworthy that, although these B-cell biomarkers were
found in peripheral blood, it is not known whether they
also localize to disease lesions in the gut.
B-cell populations that differentially express the core
B-cell gene module may trafﬁc to and from the gut or reside
permanently in peripheral blood. Analogous to T cells,52 if
July 2017 B Cell Gene Signature in Celiac Disease 15these B cells trafﬁc to the gut, then a4/b7-integrins may be
expressed in these cells. Based on our experimental design,
it was not possible to address whether integrin expression
in B cells was constitutive or inducible from baseline to the
6-week time point. Because we co-puriﬁed B and T cells as
a single pool, the resulting puriﬁed RNA reﬂects the mixture
of B and T cells. Since the number of T cells exceeds that of
B cells, and these integrins are expressed in T cells, the
puriﬁed RNA pool will reﬂect T-cell expression. Validation
studies will expand the repertoire of B-cell–speciﬁc bio-
markers, including integrins, using more sensitive meth-
odologies. These biomarkers can be used not only to track
the location, but also to isolate and characterize the pro-
posed B-cell activity that correlates with immune tolerance
in CeD.
A change in the number of B cells relative to T cells in
peripheral blood will affect the results of our study where
B and T cells were isolated as a pool. Unfortunately, the
number of B and T cells at baseline and end-of-study were
not quantiﬁed. If the number of B cells increased from
baseline to end-of-study, then we would expect that all
B-cell genes would go up as a unit. We observed that half of
the genes (24 of 48 B-cell genes, 35 of 63 B-cell probes, see
Table 2, non-correlating B-cell gene list) did not correlate
with intestinal injury, which is inconsistent with increases
to B-cell numbers only. CD20, CD79B, CR2, and FCRL2
were among the many genes that did not correlate with
intestinal injury yet are widely accepted as genes
expressed differentially in B cells relative to T cells. We do
not rule out the possibility of changes in B-cell numbers,
however, the aggregate B-cell population looked qualita-
tively different by 6 weeks.
We envision several hypothetical scenarios to model
how changes in cell number translate to changes in the
measured signal. Let us assume the total RNA yield per
sample is 100 ng for the B- and T-cell pool and that the
number of B cells is roughly 10-fold less than T cells in
peripheral blood. If the amount of total RNA used for
sample analysis is ﬁxed at 100 ng, 90 ng total RNA comes
from T cells and 10 ng comes from B cells. In the ﬁrst
scenario, if the number of B cells and the amount of RNA
contributed by B cells were to increase 2-fold, holding T
cells constant, we collect an additional 10 ng B-cell RNA
and the total RNA yield increases to 110 ng for the B- and
T-cell pool. We expect to see the B-cell signal increase
nearly 2-fold if 100 ng total RNA is used for analysis. In the
second scenario, if the number of T cells and the amount of
RNA contributed by T cells were to increase 2-fold, holding
B cells constant, then we collect an additional 90 ng RNA
and the total RNA yield increases to 190 ng RNA for the B-
and T-cell pool. We do not expect to see any increase in the
T-cell signal if 100 ng total RNA is used for sample analysis.
Changes that occurred in T cells were normalized out if the
amount of total RNA hybridized to the array was ﬁxed at
100 ng for both the baseline and end-of-study samples.
Finally, in a scenario in which we analyze only B cells
without T cells, and assuming the number of B cells and the
amount of RNA contributed by B cells were to increase
2-fold, then the total RNA yield increases from 10 ng atbaseline to 20 ng at end-of-study. We expect that normal-
ization during microarray analysis will completely elimi-
nate the 2-fold increase in the B-cell signal if 10 ng total
RNA is used for sample analysis. In this respect, the T-cell
RNA fortuitously serves as an internal control that makes it
possible to visualize a 2-fold increase in the number of B
cells described in scenario 1. Quantitative polymerase
chain reaction and cell counts will be required in validation
studies to resolve the ambiguities associated with varia-
tions in the ratio of B to T cells. Complexities associated
with relative changes in cell numbers are expanded greatly
when peripheral blood mononuclear cells or tissues are
used for analyses. In comparison, the decision to use
puriﬁed B and T cells was an advantage and not a disad-
vantage of the current experimental design.
There are two scenarios in which the current experi-
mental design performs well even in the absence of cell
counts or quantitative polymerase chain reaction. First, if
the aggregate B-cell gene expression changes for some
genes and not others, and the number of B and T cells re-
mains constant from baseline to end-of-study, we expect to
visualize these changes for both B and T cells. This scenario
includes B- and T-cell subsets that repopulate or trafﬁc to/
from peripheral blood. Second, if the number of T cells and
the amount of RNA contributed by T cells were to increase
2-fold in a small subset (say 10%) of T cells, then this
scenario for T cells is nearly identical to B cells. Given
markers speciﬁc for this T-cell subset, say Th1, we expect to
see the change. Perhaps this is why we observed a small
direct correlation of Th1 and Th2 gene expression with in-
testinal injury. T-cell subsets that otherwise would correlate
strongly with DVh:Cd but lack unique gene identiﬁers will
not be detected, which is a limitation of the current study
design. For example, it was not possible to analyze a
contribution for regulatory T cells because the number of
unique genes that distinguish this T-cell subset from other T
cells was limited. Without unique identiﬁers, a regulatory T
cell will not signiﬁcantly inﬂuence shared gene expression
proﬁles in the aggregate CD3þ T-cell population.
The genes that we used for analysis were markers of B-
and T-cell differentiation. Using B cells as an example, many
of these genes are implicated in B-cell–receptor signaling,
hence their differential expression in B cells and their
selection as B-cell markers. Even if we assume a functional
correlation between B cells and immune tolerance to gluten,
it would be premature, although intriguing, to speculate on
the possibility of modulating B-cell–receptor signaling and
B-cell activation thresholds to promote immune tolerance to
gluten. Importantly, it should not be inferred that these are
the only genes differentially expressed between tolerance
and the lack of tolerance to gluten. The data do not rule out
the possibility that the B cell could modulate immune
tolerance by a mechanism that is shared with other cells
despite the fact that we were not able to use these shared
genes in our analysis. Exactly if and how the B cell functions
to promote immune tolerance will require partial puriﬁca-
tion and characterization of the proposed cellular activity.
The genes that drive its proposed cellular function may
extend beyond the gene lists used for analysis.
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